Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (Weighted Average) (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $338715.0 as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 99.47% to $338715.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338715.0 through Dec 2025, down 99.47% year-over-year, with the annual reading at $338715.0 for FY2025, 99.47% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $338715.0 in Q4 2025 for Perspective Therapeutics, down from $74.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $264573.0 in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $79.1 million across 5 years, with a median of $71.5 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 99.81% in 2022 and later soared 11083.67% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $142.0 million in 2021, then plummeted by 99.81% to $264573.0 in 2022, then surged by 117.73% to $576063.0 in 2023, then skyrocketed by 11083.67% to $64.4 million in 2024, then tumbled by 99.47% to $338715.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CATX at $338715.0 in Q4 2025, $74.3 million in Q3 2025, and $74.2 million in Q2 2025.